IPS HEART is the first induced pluripotent stem cell company to launch in 2014 around heart disease. With over $20 million+ of funded research, we were the first to publish our moon-shot approach showing extensive heart regeneration after heart attack with over 50%+ EF improvement vs control and a 70% reduction in fibrosis. We have created extensive new functional human heart muscle in our published studies thus validating our patented IPS small molecule platform approach. With a completed FDA PRE-IND meeting and GMP manufacturing, we plan to file the first IPS IND to start clinically in the United States.
Company Details
- Employees
- 1
- Founded
- -
- Address
- 2450 Holcombe Blvd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.ipsheart.org
- HQ
- Houston, Texas
Ips Heart Questions
Ips Heart's website is https://www.ipsheart.org
Ips Heart's LinkedIn profile is https://www.linkedin.com/company/ips-heart
Ips Heart has
1 employees.
View email and phone details for 1
employees at Ips Heart.
Ips Heart's industry is
Biotechnology Research
Ips Heart's top competitors are
Aav Innovation Labs,
Adaptimmune,
Capstan Therapeutics,
Astraveus,
Tune Therapeutics,
Immunis, Inc.,
Sana Biotechnology, Inc.,
Glialign,
Bluerock Therapeutics,
Bayer.
Ips Heart's categories are Biotechnology Research
Ips Heart's founding year is 2014
